EOLS - Company ID 0001570562
Evolus, Inc. trades as EOLS. In its fiscal 2025 annual report the company posted revenue of $297.18M, up 11.6% from the prior year and net income of -$51.64M. This page tracks Evolus, Inc. through 543 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -257.8% to -17.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
| SCHEDULE 13G/A | - | 2026-03-26 |
| Insider trade | 4 | 2026-03-20 |
| Insider trade | 4 | 2026-03-20 |
The largest companies sharing Evolus, Inc.'s SEC industry classification (pharmaceutical preparations).
Evolus, Inc. reported revenue of $297.18M for fiscal year 2025, an increase of 11.6% year over year.
In its latest fiscal year Evolus, Inc. reported a net loss of $51.64M.